Chonluten

Chonluten is a synthetic tripeptide (Gly-Glu-Pro) belonging to the Khavinson peptide bioregulator series - a family of organ-specific short peptides developed over several decades in Russia for clinical applications in gerontology, preventive medicine, and tissue-specific support.

The tripeptide sequence of Chonluten was isolated from bronchopulmonary tissue and is proposed to interact with gene regulatory regions in bronchial and alveolar cells, supporting the normal pattern of protein synthesis in lung tissue. Like other bioregulators in the Khavinson system, Chonluten is positioned as a tissue-specific peptide that acts at the gene expression level to support organ function, particularly when that function has declined due to ageing, disease, or injury.

The lungs are an organ of significant biological complexity, with dozens of specialised cell types including type I and type II alveolar pneumocytes, bronchial epithelial cells, goblet cells (producing mucus), ciliated cells (mucociliary clearance), and alveolar macrophages. Type II pneumocytes produce pulmonary surfactant - the phospholipid-protein mixture that reduces surface tension in alveoli and prevents collapse during expiration. Loss of surfactant production is a critical failure point in acute respiratory distress, and the maintenance of type II pneumocyte function is a key research objective in respiratory medicine.

Russian clinical research into Chonluten has focused on its application in chronic respiratory diseases, post-infection recovery, and age-related lung function decline. In geriatric research settings, Chonluten has been studied as part of multi-bioregulator protocols aimed at supporting multiple organ systems simultaneously.

Chonluten is related to but distinct from Bronchogen (Ala-Glu-Asp-Leu), another lung-targeted bioregulator from the same research programme. The two are sometimes used together in respiratory health protocols.